The project will focus on advancing MDX-201, an innovative ADC that links a cytotoxic payload with a first-in-class monoclonal antibody (MDX-124) that targets annexin-A1.
Stevenage Bioscience Catalyst is deeply saddened to share the news that our CEO, Dr Sally Ann Forsyth OBE, passed away at home on Saturday 2 May after a long battle with illness.
Coulter Partners successfully led a search assignment for Laigo Bio and is pleased to announce the placement of Dr. Richard C.A. Sainson as its new Chief Scientific Officer (CSO).
Epitopea announced that it has received approval from MHRA and the REC for its clinical trial application (CTA) for its first-in-human clinical trial (OVACT) of CryptiVax™-1001.
Coulter Partners successfully led a search assignment for Oral Care AB and is pleased to announce the placement of Lucas Kromann as Chief Executive Officer (CEO) Denmark.
Coulter Partners successfully led a search for Babraham Research Campus Ltd (BRCL) and is pleased to announce the placement of Dr. Rich Ferrie as Chief Executive Officer (CEO).
Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases, has appointed Edwin Moses as Chair of the Board of Directors, with immediate effect.
Some of the UK’s most ambitious early-stage life science companies are choosing Victoria House as their London base, adding fresh momentum to one of the capital’s most exciting life science communities.
